CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies based on its proprietary plant-derived recombinant human collagen (rhCollagen), today reported financial results for the full year ended December 31, 2025.
The company’s performance was defined by a significant leap in top-line revenue and a disciplined restructuring program designed to extend its cash runway through high-value clinical milestones.
For the full year 2025, CollPlant reported GAAP revenue of $2.37 million, a substantial increase compared to $0.52 million in 2024.
This growth was primarily driven by a $2 million milestone payment from AbbVie related to the ongoing development of dermal fillers.
On the bottom line, the company successfully narrowed its GAAP net loss to $11.5 million, or $0.94 per share, from a net loss of $16.6 million in the prior year.
The improvement reflects a comprehensive cost-reduction strategy, including a 25% reduction in the company’s workforce and a streamlined operational footprint.
CollPlant ended the year with a cash position of $5.6 million.
Management noted that the proceeds from recent cost-cutting measures, combined with potential future milestones from existing partnerships, are intended to fund the company’s priority programs in medical aesthetics and 3D bioprinting.